Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.
about
LG-362B targets PML-RARα and blocks ATRA resistance of acute promyelocytic leukemia.Lithium Chloride Promotes Apoptosis in Human Leukemia NB4 Cells by Inhibiting Glycogen Synthase Kinase-3 Beta.Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancerRationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia.Verteporfin Inhibits Cell Proliferation and Induces Apoptosis in Human Leukemia NB4 Cells without Light Activation.Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.MiR-29 Induces K562 Cell Apoptosis by Down-Regulating FoxM1Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens.Multifactorial Modes of Action of Arsenic Trioxide in Cancer Cells as Analyzed by Classical and Network Pharmacology.The impact of Mir-9 regulation in normal and malignant hematopoiesis.Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis.
P2860
Q35969759-DC97A09F-642B-45D0-86C4-AC8EF025400CQ36189756-A0956C04-2070-4C00-840A-5EE92E853B6EQ36866821-246103E3-7031-44F9-842F-F8CC86242FFCQ37396013-766D17DA-2E56-4385-912A-8ADB0C027EC8Q38752325-4972CF54-40C8-424C-953E-D156017B63BDQ38755213-3549273F-4FCD-4D62-9047-3D37F40307EEQ41035347-84B61D1D-74B9-43B0-AB72-45B530C18793Q41464664-499F943F-539C-4C39-B21A-D147C1BA209FQ42034484-F377B885-79E4-4F60-A8E7-EF2D07BD28AFQ42699823-6C6B761F-1AA1-4E81-AAB5-246E179EC1D4Q51122167-8ED715BE-21D9-4D63-A6FA-E0DD6CC0272FQ53702218-3D0A3A1C-6897-4EA7-81F9-B5AE97F4708CQ54941919-9AAAEB3A-91B4-4292-A8CD-220D3BF2F2DFQ55362655-762C733B-7E97-4522-A6C6-5ABB92481812
P2860
Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Comparison of newly diagnosed ...... into mechanisms of resistance.
@ast
Comparison of newly diagnosed ...... into mechanisms of resistance.
@en
type
label
Comparison of newly diagnosed ...... into mechanisms of resistance.
@ast
Comparison of newly diagnosed ...... into mechanisms of resistance.
@en
prefLabel
Comparison of newly diagnosed ...... into mechanisms of resistance.
@ast
Comparison of newly diagnosed ...... into mechanisms of resistance.
@en
P2093
P2860
P50
P1433
P1476
Comparison of newly diagnosed ...... into mechanisms of resistance.
@en
P2093
Alok Srivastava
Ansu Abu Alex
Arun Jose Nellickal
Auro Viswabandya
Biju George
Ezhilarasi Chendamarai
Kavitha M Lakshmi
Mammen Chandy
Mohammed Aiyaz
Nancy Beryl Janet
P2860
P304
P356
10.1371/JOURNAL.PONE.0121912
P407
P577
2015-03-30T00:00:00Z